Brian P. Hafler

Brian P. Hafler

Auto-generated profile, based on publicly available information

Brian P. Hafler

Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMadhvi Menon
Madhvi Menon
SMShahin Mohammadi
Shahin Mohammadi
JDJose Davila-Velderrain
Jose Davila-Velderrain
BGBrittany A. Goods
Brittany A. Goods
TCTanina D. Cadwell
Tanina D. Cadwell
BHBrian P. Hafler
Brian P. Hafler
Genome-wide association studies (GWAS) have identified genetic variants associated with age-related macular degeneration (AMD), one of the leading causes of blindness in the elderly. However, it has been challenging to identify the cell types associated with AMD given the genetic complexity of the disease. Here we perform massively parallel single-cell RNA sequencing (scRNA-seq) of human retinas using two independent platforms, and report the first single-cell transcriptomic atlas of the human retina. Using a multi-resolution network-based analysis, we identify all major retinal cell types, and their corresponding gene expression signatures. Heterogeneity is observed within macroglia, suggesting that human retinal glia are more diverse than previously thought. Finally, GWAS-based enrichment analysis identifies glia, vascular cells, and cone photoreceptors to be associated with the risk of AMD. These data provide a detailed analysis of the human retina, and show how scRNA-seq can provide insight into cell types involved in complex, inflammatory genetic diseases.

5 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MKManik Kuchroo
Manik Kuchroo
MDMarcello DiStasio
Marcello DiStasio
ESEric Song
Eric Song
ECEda Calapkulu
Eda Calapkulu
LZLe Zhang
Le Zhang
BHBrian P. Hafler
Brian P. Hafler
Due to commonalities in pathophysiology, age-related macular degeneration (AMD) represents a uniquely accessible model to investigate therapies for neurodegenerative diseases, leading us to examine whether pathways of disease progression are shared across neurodegenerative conditions. Here we use single-nucleus RNA sequencing to profile lesions from 11 postmortem human retinas with age-related macular degeneration and 6 control retinas with no history of retinal disease. We create a machine-learning pipeline based on recent advances in data geometry and topology and identify activated glial populations enriched in the early phase of disease. Examining single-cell data from Alzheimer’s disease and progressive multiple sclerosis with our pipeline, we find a similar glial activation profile enriched in the early phase of these neurodegenerative diseases. In late-stage age-related macular degeneration, we identify a microglia-to-astrocyte signaling axis mediated by interleukin-1βwhich drives angiogenesis characteristic of disease pathogenesis. We validated this mechanism using in vitro and in vivo assays in mouse, identifying a possible new therapeutic target for AMD and possibly other neurodegenerative conditions. Thus, due to shared glial states, the retina provides a potential system for investigating therapeutic approaches in neurodegenerative diseases.

3 March 2016 in Seminars in Ophthalmology
Verified
Journal Article
Open access
PDF file
BHBrian P. Hafler
Brian P. Hafler
JCJason Comander
Jason Comander
CDCarol Weigel DiFranco
Carol Weigel DiFranco
EPEmily M. Place
Emily M. Place
EPEric A. Pierce
Eric A. Pierce
Mutations in pre-mRNA splicing factors are the second most common cause of autosomal dominant retinitis pigmentosa, and a major cause of vision loss. The development of gene augmentation therapy for disease caused by mutations in PRPF31 necessitates defining pretreatment characteristics and disease progression of patients with PRPF31-related retinitis pigmentosa. We show rates of decline of visual field area −6.9% per year and 30-Hz flicker cone response of −9.2% per year, which are both similar to observed rates for retinitis pigmentosa. We hypothesize that RNA splicing factor retinitis pigmentosa will be amenable to treatment by AAV-mediated gene therapy, and that understanding the clinical progression rates of PRPF31 retinitis pigmentosa will help with the design of gene therapy clinical trials.

28 February 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
KAKarina Ascunce
Karina Ascunce
RDRahul M. Dhodapkar
Rahul M. Dhodapkar
DHDeven Huang
Deven Huang
BHBrian P. Hafler
Brian P. Hafler
Age-related macular degeneration (AMD) is a neurodegenerative disease and a leading cause of irreversible vision loss in the developed world. While not classically described as an inflammatory disease, a growing body of evidence has implicated several components of the innate immune system in the pathophysiology of age-related macular degeneration. In particular, complement activation, microglial involvement, and blood-retinal-barrier disruption have been shown to play key roles in disease progression, and subsequent vision loss. This review discusses the role of the innate immune system in age-related macular degeneration as well as recent developments in single-cell transcriptomics that help advance the understanding and treatment of age-related macular degeneration. We also explore the several potential therapeutic targets for age-related macular degeneration in the context of innate immune activation.

5 May 2022 in Seminars in Immunopathology
Verified
Journal Article
Closed access
PDF file
RDRahul M. Dhodapkar
Rahul M. Dhodapkar
DMDiego Martell
Diego Martell
BHBrian P. Hafler
Brian P. Hafler

4 July 2025 in Science Advances
Verified
Journal Article
Open access
SMSean J. Miller
Sean J. Miller
RDRahul M. Dhodapkar
Rahul M. Dhodapkar
HSHande Eda Sutova
Hande Eda Sutova
YXYao Xue
Yao Xue
SLSeunghoon Lee
Seunghoon Lee
BHBrian P. Hafler
Brian P. Hafler
While the etiology of Alzheimer’s disease remains unknown, there is growing support for the amyloid-β antimicrobial hypothesis. Amyloid-β, the main component of amyloid plaques in Alzheimer’s disease, has been shown to be generated in the presence of microbes. Entrapment of microbes by aggregated amyloid-β may serve as an innate immune response to pathogenic infections. To understand the association of amyloid-β plaques and pathogenic infections in the central nervous system, we obtained viable short-interval postmortem human retinal tissue and generated human retinal organoids that contain electrophysiologically active neurons. Here, we demonstrate that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces amyloid-β extracellular protein aggregates in human retinal explants and retinal organoids. Last, pharmacological inhibition of neuropilin-1 resulted in reduced amyloid-β deposition in human retinal explants treated with SARS-CoV-2 Spike 1 protein. These results suggest that Spike 1 protein, during infection with SARS-CoV-2, can induce amyloid-β aggregation, which may be associated with the neurological symptoms experienced in COVID-19.